Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_2

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

completed125%

terminated375%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_1

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

NCT03059147

terminatedphase_1

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

NCT02337309

terminatedphase_2

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

NCT02644122

completedphase_1

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

NCT00907205

Clinical Trials (4)

Showing 4 of 4 trials

NCT03059147Phase 1

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Terminated

NCT02337309Phase 1

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Terminated

NCT02644122Phase 2

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Terminated

NCT00907205Phase 1

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4